weekly_roundup

BioTechSign Daily Catalyst Roundup - November 19, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 19, 2026

Daily Biotech Catalyst Digest: November 19, 2026

EYPT leads the current BioTechSign screen at 83.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.83.5Aclinical activity 100%, short interest 50%, dilution risk 47%
MLTXMoonLake Immunotherapeutics80.5Aclinical activity 100%, short interest 50%, publication signal 35%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
NKTRNektar Therapeutics74.4Bpublication signal 100%, short interest 90%, clinical activity 75%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%

Recent Grade-Change Queue

  • RARE (Ultragenyx Pharmaceutical) currently grades F with a 26.6/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 37%.
  • EYPT (EyePoint, Inc.) currently grades A with a 83.5/100 catalyst score. Main inputs: clinical activity 100%, short interest 50%, dilution risk 47%.
  • PTCT (PTC Therapeutics) currently grades D with a 44.2/100 catalyst score. Main inputs: clinical activity 75%, short interest 50%, dilution risk 29%.
  • ASND (Ascendis Pharma) currently grades F with a 34.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 62%, dilution risk 15%.
  • KPTI (Karyopharm Therapeutics) currently grades C with a 61.2/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 70%.
  • PRAX (Praxis Precision Medicine) currently grades D with a 45.4/100 catalyst score. Main inputs: PDUFA timing 75%, short interest 50%, clinical activity 38%.
  • KURA (Kura Oncology, Inc.) currently grades C with a 62.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 65%.
  • ANRO (Alto Neuroscience, Inc.) currently grades F with a 34.6/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 50%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.